ArticleMolecular therapy. Advances2026

Rapamycin nanoparticles mitigate anti-AAV antibody formation in a mouse model of ornithine transcarbamylase deficiency.

Antonio Vicidomini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.